The two most widely available Chinese coronavirus vaccines use technology that uses an inactivated version of the virus to produce an immune response — an older though more established technology than the messenger RNA platform used by vaccines widely available in the United States and Europe.
However, some studies now suggest that two doses of these vaccines, which are produced by Sinopharm and Sinovac, may provide relatively lower protection against omicron. The Post’s Eva Dou and Lyric Li reported Monday that China is facing the looming question of how to administer booster shots to its population of 1.4 billion, of whom more than 80 percent have been vaccinated, mostly with Sinopharm and Sinovac.
